All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for AMGEN · Biotechnology.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · California · House · Senate · $60,000.00 income · posted Jul 20, 2026

Official filing document

Bills named in this filing 5

S 3788
CLEAR LABELS Act
S 3014
Ensuring Timely Access to Generics Act of 2025
S 1954
Biosimilar Red Tape Elimination Act
S 2658
Medication Affordability and Patent Integrity Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 5

Medicare/Medicaid

Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. Issues related to the Most Favored Nation drug pricing.

Health Issues

Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act. S. 3014, Ensuring Timely Access to Generics Act of 2025; S. 1954, Biosimilar Red Tape Elimination Act; S. 2658, Medication Affordability and Patent Integrity Act.

Monitored issues related to intellectual property.

Taxation/Internal Revenue Code

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.

Trade (domestic/foreign)

Issues related to tariffs. Issues related to drug pricing.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.